DUBLIN–(BUSINESS WIRE)–The “Phenylketonuria Treatment Market: A Research Perspective” report has been added to ResearchAndMarkets.com’s offering.
This report details the phenylketonuria treatment market. It also highlights current and future market potential along with a detailed analysis of the competitive environment, product advancements, and dynamics such as market drivers and factors restraining market growth.
The report also covers market projections through 2025 and includes company profiles. The report details segments such as treatment type and geographical region. For market estimates, data have been provided for 2019 as the base year, with projections for 2020 and 2025.
The goals of this study were to understand the current market scenario for the treatment options of phenylketonuria (PKU) which includes food for medical purposes (FSMPs) and to assess the market’s growth potential through the end of 2025.
This study explores market dynamics such as drivers, restraints, opportunities, and trends that impact the growth of the market. The main objective of the study is to present a comprehensive analysis of the current treatment market for phenylketonuria and the future directions of the market.
The phenylketonuria treatment market is currently growing, with a strong drug pipeline and upcoming treatment methods for the maintenance of this condition. Phenylketonuria is a genetic disorder that is inherited from the parents. It is a birth defect that results in the accumulation of amino acid phenylalanine due to low levels of the enzyme phenylalanine hydroxylase. It is a condition that demands life-long maintenance; there is no proper medication to treat it.
This market has grown steadily since 2014, and the pipeline shows tremendous potential growth during the forecast period. Many major companies are working toward developing novel products and funding innovations and R&D. Market growth is also attributed to companies concentrating on strategic investments and acquisitions.
The Report Includes:
- Explanation of the major drivers and regional dynamics of the global phenylketonuria market and evaluation of market size, market forecast, market share analysis, and a relevant patent analysis
- Impact analysis of COVID-19 on the phenylketonuria market
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry
Key Topics Covered:
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of this Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst’s Credentials
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Disease Background and Market Dynamics
- Disease Background
- Overview
- Diagnosis
- Epidemiology
- Treatment
- Market Dynamics
- Market Drivers
- Market Restraints
- Impact of COVID-19 on PKU Treatment Market
Chapter 4 Market Breakdown by Treatment Type
- Medication
- Supplements
- Other Treatment Types
Chapter 5 Market Breakdown by Region
- North America
- Market Size and Forecast
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Chapter 6 Company Profiles
- Abbott Nutrition
- APR Applied Pharma Research S.A.
- Biomarin Pharmaceutical Inc.
- Censa Pharmaceuticals
- Nestle Health Science
For more information about this report visit https://www.researchandmarkets.com/r/wp83l7
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900